- Home
- CNTB vs CUE Comparison
CNTB vs CUE Comparison
Compare CNTB & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTB
- CUE
- Stock Information
- Founded
- CNTB 2012
- CUE 2014
- Country
- CNTB United States
- CUE United States
- Employees
- CNTB N/A
- CUE N/A
- Industry
- CNTB Biotechnology: Pharmaceutical Preparations
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- CNTB Health Care
- CUE Health Care
- Exchange
- CNTB Nasdaq
- CUE Nasdaq
- Market Cap
- CNTB 55.2M
- CUE 60.6M
- IPO Year
- CNTB 2021
- CUE 2018
- Fundamental
- Price
- CNTB $0.67
- CUE $0.79
- Analyst Decision
- CNTB Strong Buy
- CUE Strong Buy
- Analyst Count
- CNTB 1
- CUE 3
- Target Price
- CNTB $8.00
- CUE $3.00
- AVG Volume (30 Days)
- CNTB 269.3K
- CUE 211.2K
- Earning Date
- CNTB 03-31-2025
- CUE 05-08-2025
- Dividend Yield
- CNTB N/A
- CUE N/A
- EPS Growth
- CNTB N/A
- CUE N/A
- EPS
- CNTB N/A
- CUE N/A
- Revenue
- CNTB $26,033,000.00
- CUE $9,287,000.00
- Revenue This Year
- CNTB N/A
- CUE N/A
- Revenue Next Year
- CNTB N/A
- CUE $4.77
- P/E Ratio
- CNTB N/A
- CUE N/A
- Revenue Growth
- CNTB N/A
- CUE 69.16
- 52 Week Low
- CNTB $0.51
- CUE $0.45
- 52 Week High
- CNTB $2.08
- CUE $2.26
- Technical
- Relative Strength Index (RSI)
- CNTB 47.33
- CUE 41.54
- Support Level
- CNTB $0.65
- CUE $0.74
- Resistance Level
- CNTB $1.00
- CUE $0.83
- Average True Range (ATR)
- CNTB 0.11
- CUE 0.09
- MACD
- CNTB 0.02
- CUE 0.02
- Stochastic Oscillator
- CNTB 38.78
- CUE 63.66
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.